In brief: C3, DNT, Starpharma, synchrotron
Tuesday, 29 March, 2005
Clinical Cell Culture (C3, ASX:CCE) has received its first batch of stocking orders for its ReCell device used to treat small burns and scars from its European distributor network. The orders have a sales value in excess of AUD$700,000 and are estimated to represent 3-6 months' worth of orders. CEO Troels Jordansen said the first batch of product was expected to be delivered in May or June of this year, with the earliest patients likely to be treated in June or July.
US company Dendritic NanoTechnologies, which is 33 per cent owned by former Australian pooled development fund Starpharma (ASX:SPL), has appointed Dow Chemical Company's licensing manager Mike Pirc to its board of directors. The appointment follows the transfer of Dow's portfolio of dendrimer patents to DNT in January in a deal that gave the company control of the majority of IP in the dendrimer field. Dow also holds a significant equity stake in DNT.
The first of multiple iHawk control systems has been delivered to the Australian Synchrotron Project by US company Concurrent Computer Corp. The systems, which are powered by RedHawk real-time Linux, were said to be selected for their response and high performance capabilities to respond to the synchrotron's data acquisition and I/O control (IOC) system requirements, and will form the foundation control system of the synchrotron light beam storage ring.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
